232 related articles for article (PubMed ID: 29318728)
1. Diagnosis and management of hyponatraemia in the older patient.
Woodward M; Gonski P; Grossmann M; Obeid J; Scholes R; Topliss DJ
Intern Med J; 2018 Jan; 48 Suppl 1():5-12. PubMed ID: 29318728
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
Rajendran R; Grossman AB; Kar P
Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335
[TBL] [Abstract][Full Text] [Related]
3. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
Humayun MA; Cranston IC
BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
[TBL] [Abstract][Full Text] [Related]
4. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
[TBL] [Abstract][Full Text] [Related]
5. Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial.
Warren AM; Grossmann M; Hoermann R; Zajac JD; Russell N
Trials; 2022 Apr; 23(1):335. PubMed ID: 35449020
[TBL] [Abstract][Full Text] [Related]
6. Tolvaptan.
Plosker GL
Drugs; 2010 Mar; 70(4):443-54. PubMed ID: 20205486
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
[TBL] [Abstract][Full Text] [Related]
8. Tolvaptan.
Ghali JK; Hamad B; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2009 Aug; 8(8):611-2. PubMed ID: 19644472
[TBL] [Abstract][Full Text] [Related]
9. Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions.
Urso C; Brucculeri S; Caimi G
J Clin Pharm Ther; 2015 Aug; 40(4):376-85. PubMed ID: 25924179
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of vasopressin receptor antagonists.
Ali F; Guglin M; Vaitkevicius P; Ghali JK
Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
12. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
Verbalis JG; Ellison H; Hobart M; Krasa H; Ouyang J; Czerwiec FS;
Am J Kidney Dis; 2016 Jun; 67(6):893-901. PubMed ID: 26874645
[TBL] [Abstract][Full Text] [Related]
13. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
Jia JD; Xie W; Ding HG; Mao H; Guo H; Li Y; Wang X; Wang JF; Lu W; Li CZ; Mao Y; Wang GQ; Gao YQ; Wang B; Zhang Q; Ge Y; Wong VW
Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan and urea in paediatric hyponatraemia.
Veligratli F; Alexandrou D; Shah S; Amin R; Dattani M; Gan HW; Famuboni A; Lopez-Garcia C; Trompeter R; Bockenhauer D
Pediatr Nephrol; 2024 Jan; 39(1):177-183. PubMed ID: 37466863
[TBL] [Abstract][Full Text] [Related]
15. Non-peptide arginine-vasopressin antagonists: the vaptans.
Decaux G; Soupart A; Vassart G
Lancet; 2008 May; 371(9624):1624-32. PubMed ID: 18468546
[TBL] [Abstract][Full Text] [Related]
16. Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
Pose-Reino A; Runkle de la Vega I; de Jong-Laird A; Kabra M; Lindner U
Adv Ther; 2021 Feb; 38(2):1055-1067. PubMed ID: 33306187
[TBL] [Abstract][Full Text] [Related]
17. Unusual case of hyponatraemia.
Hannaway RK; Cowie F; Jude E
BMJ Case Rep; 2012 Aug; 2012():. PubMed ID: 22854232
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of hyponatraemia in hospitalised patients.
Reddy P; Mooradian AD
Int J Clin Pract; 2009 Oct; 63(10):1494-508. PubMed ID: 19769706
[TBL] [Abstract][Full Text] [Related]
19. Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis.
Ahluwalia V; Heuman DM; Feldman G; Wade JB; Thacker LR; Gavis E; Gilles H; Unser A; White MB; Bajaj JS
J Hepatol; 2015 Jan; 62(1):75-82. PubMed ID: 25111174
[TBL] [Abstract][Full Text] [Related]
20. [Hyponatraemia in elderly patient - significance, clarification and therapy].
Gosch M
Dtsch Med Wochenschr; 2022 Mar; 147(6):301-305. PubMed ID: 35291034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
